Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications cost effectiveness nusinersen treatment patients infantile onset later onset spinal
… type 2 (CLN2) disease Duchenne muscular dystrophy Spinal muscular atrophy Types of Projects We have implemented …
… on projects to research cutaneous diseases, cutaneous treatment, and complications and comorbidities of cutaneous … Benefit-risk preference studies Decision-analytic models (cost effectiveness, budget impact) Drug utilization studies …
… use in clinical trials involving both pediatric and adult patients across a wide range of conditions. In addition, we … including regulatory submissions, reports, and publications Support to secure regulatory acceptability of …
… our clients on projects to research ocular disease, ocular treatment, and complications and comorbidities of ocular … and longitudinal data sources Decision-analytic models (cost effectiveness, budget impact) Drug utilization studies …
… Effective treatments can benefit caregivers as well as patients. However, inclusion of caregiver benefits into …
… last five years, the US FDA has advocated for including patients’ voice in drug development and has issued new … industry has continued to invest heavily in new cancer treatment research. To better understand how PRO measures …
… and thereby potentially reduce the need for CT scanning in patients with mTBI. Substantial resources are often used in assessing and treating patients with mTBI. Being able to determine the absence of … comparison to S100B in the current model. In addition to cost savings, using biomarker testing could free up resources …
… Priorities, Real-World Evidence, and the Safety and Effectiveness of COVID-19 Vaccines Share on: November 2, … methods, and support for performing studies. The Biologics Effectiveness and Safety (BEST) System supports the Sentinel Initiative in monitoring the safety and effectiveness of biologic products. RTI-HS is in the trenches …
… for Population Therapeutics Conference. Updated cost-utility and public health impact of recombinant zoster … J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Cost-effectiveness and public health impact of recombinant zoster …
… of payers interviewed reported they would use an ICER cost-effectiveness threshold price as a basis for negotiating …